Cardiac Fibrosis Is Associated With Decreased Circulating Levels of Full-Length CILP in Heart Failure

Shuin Park; Sara Ranjbarvaziri; Peng Zhao; Reza Ardehali

doi:10.1016/j.jacbts.2020.01.016

Cardiac Fibrosis Is Associated With Decreased Circulating Levels of Full-Length CILP in Heart Failure

JACC Basic Transl Sci. 2020 Apr 15;5(5):432-443. doi: 10.1016/j.jacbts.2020.01.016. eCollection 2020 May.

Authors

Shuin Park^{1

2

3}, Sara Ranjbarvaziri^{1

2

3}, Peng Zhao¹, Reza Ardehali^{1

2

3

4}

Affiliations

¹ Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California.
² Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles (UCLA), Los Angeles, California.
³ Molecular, Cellular, and Integrative Physiology Graduate Program, University of California, Los Angeles (UCLA), Los Angeles, California.
⁴ Molecular Biology Institute, UCLA, Los Angeles, California.

Abstract

Cardiac fibrosis is a pathological process associated with various forms of heart failure. This study identified latent transforming growth factor-β binding protein 2, cartilage oligomeric matrix protein, and cartilage intermediate layer protein 1 as potential biomarkers for cardiac fibrosis. All 3 encoded proteins showed increased expression in fibroblasts after transforming growth factor-β stimulation in vitro and localized specifically to fibrotic regions in vivo. Of the 3, only the full-length cartilage intermediate layer protein 1 showed a significant decrease in circulating levels in patients with heart failure compared with healthy volunteers. Further studies on these 3 proteins will lead to a better understanding of their biomarker potential for cardiac fibrosis.

Keywords: CFB, cardiac fibroblast; CILP, cartilage intermediate layer protein 1; COMP, cartilage oligomeric matrix protein; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; Ltbp2, latent transforming growth factor-β binding protein 2; PCR, polymerase chain reaction; RNA, ribonucleic acid; TAC, transverse aortic constriction; TGF, transforming growth factor; biomarker; cardiac fibrosis; extracellular matrix protein; heart failure.

Abstract

Grants and funding